BACKGROUND & AIMS:N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure. METHODS: In a prospective, double-blind trial, acute liver failure patients without clinical or historical evidence of acetaminophen overdose were stratified by site and coma grade and assigned randomly to groups that were given NAC or placebo (dextrose) infusion for 72 hours. The primary outcome was overall survival at 3 weeks. Secondary outcomes included transplant-free survival and rate of transplantation. RESULTS: A total of 173 patients receivedNAC (n = 81) or placebo (n = 92). Overall survival at 3 weeks was 70% for patients given NAC and 66% for patients given placebo (1-sided P = .283). Transplant-free survival was significantly better for NAC patients (40%) than for those given placebo (27%; 1-sided P = .043). The benefits of transplant-free survival were confined to the 114 patients with coma grades I-II who received NAC (52% compared with 30% for placebo; 1-sided P = .010); transplant-free survival for the 59 patients with coma grades III-IV was 9% in those given NAC and 22% in those given placebo (1-sided P = .912). The transplantation rate was lower in the NAC group but was not significantly different between groups (32% vs 45%; P = .093). Intravenous NAC generally was well tolerated; only nausea and vomiting occurred significantly more frequently in the NAC group (14% vs 4%; P = .031). CONCLUSIONS:Intravenous NAC improves transplant-free survival in patients with early stage non-acetaminophen-related acute liver failure. Patients with advanced coma grades do not benefit from NAC and typically require emergency liver transplantation.
RCT Entities:
BACKGROUND & AIMS:N-acetylcysteine (NAC), an antidote for acetaminophenpoisoning, might benefit patients with non-acetaminophen-related acute liver failure. METHODS: In a prospective, double-blind trial, acute liver failurepatients without clinical or historical evidence of acetaminophenoverdose were stratified by site and coma grade and assigned randomly to groups that were given NAC or placebo (dextrose) infusion for 72 hours. The primary outcome was overall survival at 3 weeks. Secondary outcomes included transplant-free survival and rate of transplantation. RESULTS: A total of 173 patients received NAC (n = 81) or placebo (n = 92). Overall survival at 3 weeks was 70% for patients given NAC and 66% for patients given placebo (1-sided P = .283). Transplant-free survival was significantly better for NACpatients (40%) than for those given placebo (27%; 1-sided P = .043). The benefits of transplant-free survival were confined to the 114 patients with coma grades I-II who received NAC (52% compared with 30% for placebo; 1-sided P = .010); transplant-free survival for the 59 patients with coma grades III-IV was 9% in those given NAC and 22% in those given placebo (1-sided P = .912). The transplantation rate was lower in the NAC group but was not significantly different between groups (32% vs 45%; P = .093). Intravenous NAC generally was well tolerated; only nausea and vomiting occurred significantly more frequently in the NAC group (14% vs 4%; P = .031). CONCLUSIONS: Intravenous NAC improves transplant-free survival in patients with early stage non-acetaminophen-related acute liver failure. Patients with advanced coma grades do not benefit from NAC and typically require emergency liver transplantation.
Authors: George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee Journal: Ann Intern Med Date: 2002-12-17 Impact factor: 25.391
Authors: Aezam Katoonizadeh; Jochen Decaestecker; Alexander Wilmer; Raymond Aerts; Chris Verslype; Werner Vansteenbergen; Paul Yap; Johan Fevery; Tania Roskams; Jacques Pirenne; Frederik Nevens Journal: Liver Int Date: 2007-04 Impact factor: 5.828
Authors: Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682
Authors: Walter K Kremers; Marrije van IJperen; W Ray Kim; Richard B Freeman; Ann M Harper; Patrick S Kamath; Russell H Wiesner Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Ortrud Vargas Hein; Renate Ohring; Andreas Schilling; Michael Oellerich; Victor W Armstrong; Wolfgang J Kox; Claudia Spies Journal: Crit Care Date: 2004-01-22 Impact factor: 9.097
Authors: Pavel Strnad; Qin Zhou; Shinichiro Hanada; Laura C Lazzeroni; Bi Hui Zhong; Phillip So; Timothy J Davern; William M Lee; M Bishr Omary Journal: Gastroenterology Date: 2010-06-09 Impact factor: 22.682
Authors: Ravindu S Kumarasena; S Mananjala Senanayake; Krishan Sivaraman; Arjuna P de Silva; Anuradha S Dassanayake; Ranjan Premaratna; Bandula Wijesiriwardena; H Janaka de Silva Journal: Hepatol Int Date: 2010-05-28 Impact factor: 6.047